Literature DB >> 18216293

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Michael Hallek1, Bruce D Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillaume Dighiero, Hartmut Döhner, Peter Hillmen, Michael J Keating, Emili Montserrat, Kanti R Rai, Thomas J Kipps.   

Abstract

Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute-sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.

Entities:  

Mesh：

Year:  2008        PMID： 18216293      PMCID： PMC2972576          DOI： 10.1182/blood-2007-06-093906

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  67 in total

1.  Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.

Authors:  M Hallek; I Langenmayer; C Nerl; W Knauf; H Dietzfelbinger; D Adorf; M Ostwald; R Busch; I Kuhn-Hallek; E Thiel; B Emmerich
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

2.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

Authors:  H Ozer; J O Armitage; C L Bennett; J Crawford; G D Demetri; P A Pizzo; C A Schiffer; T J Smith; G Somlo; J C Wade; J L Wade; R J Winn; A J Wozniak; M R Somerfield
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

3.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

4.  Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-05-19       Impact factor: 13.506

5.  Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.

Authors:  Barbara F Eichhorst; Raymonde Busch; Tanja Obwandner; Ingrid Kuhn-Hallek; Peter Herschbach; Michael Hallek
Journal:  J Clin Oncol       Date:  2007-03-26       Impact factor: 44.544

6.  Management of cancer in the older person: a practical approach.

Authors:  L Balducci; M Extermann
Journal:  Oncologist       Date:  2000

7.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia.

Authors:  Ana Muntañola; Francesc Bosch; Pedro Arguis; Eduardo Arellano-Rodrigo; Carmen Ayuso; Eva Giné; Marta Crespo; Pau Abrisqueta; Carol Moreno; Francesc Cobo; Armando López-Guillermo; Emili Montserrat
Journal:  J Clin Oncol       Date:  2007-03-12       Impact factor: 44.544

9.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Hagop Kantarjian; Michael Keating
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

10.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

Authors:  A C Rawstron; N Villamor; M Ritgen; S Böttcher; P Ghia; J L Zehnder; G Lozanski; D Colomer; C Moreno; M Geuna; P A S Evans; Y Natkunam; S E Coutre; E D Avery; L Z Rassenti; T J Kipps; F Caligaris-Cappio; M Kneba; J C Byrd; M J Hallek; E Montserrat; P Hillmen
Journal:  Leukemia       Date:  2007-03-15       Impact factor: 11.528
View more
  1060 in total

1.  Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Mahmood Jeddi-Tehrani; Bita Ansaripour; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Fazel Shokri
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

2.  [Chronic lymphocytic leukemia: current standards and novel approaches].

Authors:  E Tausch; S Stilgenbauer
Journal:  Internist (Berl)       Date:  2014-12       Impact factor: 0.743

3.  miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Angelo Veronese; Laura Z Rassenti; Veronica Balatti; Dennis K Pearl; Mario Acunzo; Stefano Volinia; Cristian Taccioli; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

4.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

5.  High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.

Authors:  Aaron C Logan; Hong Gao; Chunlin Wang; Bita Sahaf; Carol D Jones; Eleanor L Marshall; Ismael Buño; Randall Armstrong; Andrew Z Fire; Kenneth I Weinberg; Michael Mindrinos; James L Zehnder; Scott D Boyd; Wenzhong Xiao; Ronald W Davis; David B Miklos
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 6.  The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.

Authors:  Jennifer R Brown; Florence Cymbalista; Jeff Sharman; Ira Jacobs; Pilar Nava-Parada; Anthony Mato
Journal:  Oncologist       Date:  2017-12-06

7.  Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Authors:  John C Byrd; Amy S Ruppert; Nyla A Heerema; Alese E Halvorson; Eva Hoke; Mitchell R Smith; John E Godwin; Stephen Couban; Todd A Fehniger; Michael J Thirman; Martin S Tallman; Frederick R Appelbaum; Richard M Stone; Sue Robinson; Julie E Chang; Sumithra J Mandrekar; Richard A Larson
Journal:  Blood Adv       Date:  2018-07-24

8.  Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.

Authors:  Hideyuki Nakazawa; Sayaka Nishina; Yuto Mimura; Toru Kawakami; Yasushi Senoo; Kaoko Sakai; Ko Nakazawa; Kiyoshi Kitano
Journal:  Int J Hematol       Date:  2014-03-02       Impact factor: 2.490

9.  Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.

Authors:  Valentin Goede; Paula Cramer; Raymonde Busch; Manuela Bergmann; Martina Stauch; Georg Hopfinger; Stephan Stilgenbauer; Hartmut Döhner; Anne Westermann; Clemens M Wendtner; Barbara Eichhorst; Michael Hallek
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

10.  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Michael J Conte; Deborah A Bowen; Gregory A Wiseman; Kari G Rabe; Susan L Slager; Susan M Schwager; Timothy G Call; David S Viswanatha; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2014-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.